Clinical Outcomes and Budget Impact of Cobas® Egfr Mutation Test Versus Sanger Sequencing in the Treatment of Locally Advanced or Metastatic Nsclc: A United States Payer Perspective
Value in Health - United Kingdom
doi 10.1016/j.jval.2014.03.445
Full Text
Open PDFAbstract
Available in full text
Date
May 1, 2014
Authors
Publisher
Elsevier BV